Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0243
The Role of Anti-dsDNA Antibodies in Predicting Incident Lupus Nephritis in Newly Diagnosed Lupus
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0156
The Role of Biological Treatment in the Health-Related Quality of Life of Ankylosing Spondylitis Patients’ Assessment – Meta-Analysis
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0076
The Role of Interferon Kappa in Psoriasis
Innate Immunity Poster- 9:00AM-11:00AM
-
Abstract Number: 0062
The Role of PGLYRP1 in the Pathogenesis of Lyme Disease
Innate Immunity Poster- 9:00AM-11:00AM
-
Abstract Number: 0315
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0088
The Spectrum of Hemophagocytic Lymphohistiocytosis: Autoimmunity vs. Malignancy
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing- 9:00AM-11:00AM
-
Abstract Number: 0294
Tired T-Cells and Monocytes with Malaise: Investigating the Links Between Cellular Iron Deficiency and Mitochondrial Dysfunction in Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0297
Towards a Glucocorticoid Exposure Signature in SLE: Effects of Type I Interferon
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0145
Treat-to-Target in Rheumatoid Arthritis: Rates of Treatment Changes in Patients Engaged with Care Management Services Compared to Historically Reported National Registry Based Estimates
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0154
Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data from the ArthritisPower Registry
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA- 9:00AM-11:00AM
-
Abstract Number: 0231
Treatment Patterns of Biologic/Targeted Synthetic DMARDs for the Management of Rheumatoid Arthritis in Australia: An Analysis of the OPAL Dataset
RA – Treatments Poster I: RA Treatments & Their Safety- 9:00AM-11:00AM
-
Abstract Number: 0278
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations